动脉粥样硬化性心血管疾病分层管理下的血脂干预措施新进展

New Advances in Lipid Interventions under Stratified Management of Atherosclerotic Cardiovascular Disease

动脉粥样硬化性心血管疾病(ASCVD)是全球范围内危害最大,疾病负担最重的慢性病类型之一。为积极控制ASCVD疾病危害,2023年我国更新了血脂管理指南,其中详述了最新的ASCVD风险评估方案以及对于不同ASCVD风险分层人群的血脂管理靶标和干预措施建议。本文将结合中国血脂管理指南(2023年)的建议,浅析近年来各类血脂干预措施的新进展。

Atherosclerotic cardiovascular disease (ASCVD) is one of the most harmful chronic diseases with the highest burden worldwide. In order to actively control the risk of ASCVD, China’s lipid management guidelines were updated in 2023, which detailed the latest ASCVD risk stratification as well as the recommendations of lipid management targets and interventions for different ASCVD risk populations. In this article, we will describe the new advances in various lipid interventions in recent years, taking into account the recommendations of the Chinese Guidelines for Lipid Management (2023).